Skip to content

    FDA: Cosmetic Use Appears Safe

    WebMD Health News

    Black Box Warning for Botox

    April 30, 2009 -- The FDA announced today that it will require black box labeling on Botox and similar products warning of a rare but potentially life-threatening complication when the effects of the toxin spread far beyond the injection site.

    The move stems from reported hospitalizations and deaths attributed to botulism poisoning in children with cerebral palsy treated with botulinum toxin for muscle spasms.

    Hospitalizations requiring ventilation have also been reported in adults treated with botulinum toxin for involuntary muscle movement and frequent neck spasms. Deaths among adults are suspected but could not be confirmed.

    No serious side effects related to the distant spread of toxin have been confirmed among people who have used Botox and the related product Myobloc for cosmetic purposes.

    Cosmetic Use Appears Safe

    Such uses generally require much smaller doses of the toxin. Cosmetic use appears safe if the products are used as directed, an FDA official told reporters Thursday.

    “If the drug is given the way it is intended, as described on the label, the risk of distant spread may well be zero,” said Ellis F. Unger, MD, of the FDA’s Center for Drug Evaluation and Research.

    Unger declined to speculate on the number of hospitalizations and deaths from botulism poisoning that have occurred in Botox and Myobloc users.

    But the health advocacy group Public Citizen, which petitioned the FDA for the black box warning, claims that as of early last year the drug was responsible for 180 serious adverse events and 16 deaths in the United States.

    The signs and symptoms of distant spread and botulism poisoning in Botox users are many, including unexplained sudden loss of strength or muscle weakness, hoarseness or trouble talking, trouble saying words clearly, loss of bladder control, trouble breathing or swallowing, double vision, blurred vision, or drooping eyelids.

    Action Affects New Botox Rival

    The FDA action affects Botox and Botox Cosmetic, both sold by Allergan Inc.; Myobloc, sold by Solstice Neuroscience; and a third botulinum toxin product -- Dysport (marketed by Ipsen) -- approved just yesterday by the FDA.

    The products are approved to treat uncontrolled muscle contractions in the neck and shoulder -- a condition known medically as cervical dystonia. Approved cosmetic uses include treating frown lines between the eyebrows and excessive underarm sweating.

    URAC: Accredited Health Web Site TRUSTe online privacy certification HONcode Seal AdChoices